Vyleesi is a Subcutaneous Injection in the Human Prescription Drug category. It is labeled and distributed by Palatin Technologies. The primary component is Bremelanotide Acetate.
Product ID | 80064-141_2935c1f6-2000-47a2-aec9-43589ce521de |
NDC | 80064-141 |
Product Type | Human Prescription Drug |
Proprietary Name | Vyleesi |
Generic Name | Bremelanotide |
Dosage Form | Injection |
Route of Administration | SUBCUTANEOUS |
Marketing Start Date | 2019-06-21 |
Marketing Category | NDA / NDA |
Application Number | NDA210557 |
Labeler Name | Palatin Technologies |
Substance Name | BREMELANOTIDE ACETATE |
Active Ingredient Strength | 2 mg/.3mL |
NDC Exclude Flag | N |
Listing Certified Through | 2021-12-31 |
Marketing Start Date | 2019-06-21 |
NDC Exclude Flag | N |
Sample Package? | N |
NDC | Brand Name | Generic Name |
---|---|---|
64011-701 | Vyleesi | bremelanotide |
80064-141 | Vyleesi | bremelanotide |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
VYLEESI 87665906 5897765 Live/Registered |
AMAG Pharmaceuticals, Inc. 2017-10-31 |